Epithalon Without Prescription: No Approval, Only a Certificate

The 503A framework exists because a compounding pharmacy needs a lawful source of raw substance. FDA's own framing is that a bulk substance qualifies where it has an applicable USP or NF monograph, or is a component of an FDA approved drug, or appears on the 503A bulks list. The category lists, most recently updated on 14 May 2026, are how nominated substances are sorted while that list is built.

The distinction matters because the stale version of this fact circulates widely. Saying that Epitalon was in category 2 under the interim policies is accurate history. Saying that it is category 2 is simply wrong, because a withdrawn nomination is not a category placement. Today it sits on no category list at all, which is a weaker position than category 2 rather than a stronger one, since a placement at least records a view and a withdrawal records none.

The practical consequence is one sentence long. A 503A pharmacy has no lawful route to compound a preparation from this substance, so there is no prescription version to seek out and no clinic that can lawfully have one made. Selank and Semax sit in exactly the same table for exactly the same reason, and our Selank legal position page and Semax legal position page set out the same framework on those two.

Three categories of product exist in this space and the compound occupies only one of them.

The fourth row is the whole market. A research listing is not a pharmacy, does not involve a prescriber, carries no pharmacy oversight of what is dispensed, and is explicit on its own face that the material is not for human consumption. That label is not a formality being worked around. It is the description of what the transaction is.

Which is why the documentation carries the entire weight here. With no approval, no monograph and no dispensing pharmacist in the chain, a certificate of analysis tied to a batch number is the only thing standing between a listing and an assertion. That is a thin form of assurance and it is the only one on offer, and the honest way to buy in this channel is to treat the paperwork as the product specification rather than as marketing.

The agency has published exactly what worries it about this compound, and it is worth reading once rather than being paraphrased into something vaguer.

"Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration."

Two separate statements are doing different work. The first is a mechanistic concern about aggregation and impurities, both of which are measurable properties of a manufactured batch rather than properties of the molecule itself. The second is an absence: the agency is saying it does not have the information, which is not a finding of harm and is also not a clearance.

The consequence for anyone reading a certificate is that the tests which speak to FDA's concern are not the one most listings lead with. Purity of 99.312% against a greater than 98% specification says the chromatogram is clean. The endotoxin and sterility lines speak to contamination, and aggregation is a physical state that a purity figure does not directly report at all. On this certificate the endotoxin line is marked PASS against a limit of 0.5 EU/mL with no measured value printed and no method named, so nothing on its face says whether the compendial bacterial endotoxins test at USP Chapter 85 was performed. A pass against a limit is a real result and a less informative one than a number.

One certificate exists for this compound, unlike the two published for Selank and for Semax. It is a single data point describing a single batch, and it is worth reading for what it covers and where it stops.

• Covered. Purity 99.312% by reversed phase HPLC on a C18 column at 214 nm; net content 9.64 mg against a specification of 10 mg plus or minus 10 percent; identity confirmed by LC-MS; endotoxin safety screen PASS against 0.5 EU/mL; microbial sterility screen showing no growth; heavy metals negative for arsenic, cadmium, lead and mercury. Report KVR-2026-A36FF4 from Kovera Labs, certified 23 May 2026, with a verification access code of 5GSZLSD.
• Not covered. Whether the substance is safe in a human, which is the question FDA says it lacks the information to answer. A sterility screen returning no growth on one batch is a screen, not a guarantee, and the certificate makes no claim beyond the batch it names.
• The number that runs against the seller. The measured 9.64 mg is 3.6 percent under the 10 mg label. It passes the stated tolerance and it is still less than the cap says, which puts the real cost at $2.59 per milligram rather than $2.50. The same vendor's Selank lot assayed at 12.29 mg and its Semax batch at 11.23 mg, both over their labels, so this is batch variation being published rather than concealed.

Nothing in that list turns research material into a medicine, and no volume of testing would. Testing answers what is in the vial. Approval answers whether the contents should be given to a person, and that question has not been asked of this substance in any forum that could answer it.

Epithalon is marketed almost entirely on telomere and longevity claims, and the provenance of those claims is part of the legal picture rather than separate from it.

The compound was developed in Russia by Vladimir Khavinson, derived by directed synthesis from the amino acid composition of a bovine pineal extract called epithalamin. Most of the supporting work comes from that group, in cell culture, rodents and fruit flies, much of it published in Russian-language journals, with limited independent replication in the Western literature. Reporting that the claims exist and who makes them is accurate. Adopting them is not, and nothing in that body of work establishes an effect on human lifespan.

The reason this belongs on a page about prescriptions is that the gap between what is claimed and what is approved is exactly the gap the regulatory position describes. A compound with an approval has been through a process that weighed its claims against evidence. This one has been through a nomination that was withdrawn, which weighed nothing. Our Epitalon reference page sets out what the published literature does and does not say, and this page prices what is actually being sold, which is 10 mg of powder in a vial with a certificate attached.